stockrow
Friday 6 November 2026
Export CNTB’s income statement to Excel — free account
Connect Biopharma Holdings Limited Sponsored ADR
CNTB Healthcare Biotechnology
Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024.
- Revenue
- +296.6%
- EPS
- −17.4%
- Free cash flow
- −23.5%
- Total debt
- −61.0%
Quarter to June 2026, against a year earlier
0.73
0.00
0.00%
Follow CNTB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 26 | 0 | 3 | (99.8%) | 50 | 88 | 89 | +1,017.6% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | (14) | (24) | (119) | (205) | (118) | (62) | (15) | (55) | (69) | +21.4% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (59.17) | (86,379.69) | (2,292.40) | (86,379.7) pt | ||||||
| Net income | — | 0 | (12) | (24) | (119) | (205) | (118) | (62) | (16) | (55) | (69) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 0.00 | 0.05 | n/m | |||||
| Earnings | — | — | (0.20) | (0.42) | (4.02) | (3.90) | (2.10) | (1.08) | (0.28) | (1.00) | (1.19) | +25.8% | ||||||
| Cash flow | — | — | (0.18) | (0.23) | (0.86) | (1.64) | (1.84) | (0.87) | (0.43) | (0.92) | (0.96) | +26.1% | ||||||
| Capex | — | — | 0.00 | 0.00 | (0.08) | (0.08) | (0.08) | 0.05 | (0.01) | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.18) | (0.23) | (0.94) | (1.71) | (1.92) | (0.81) | (0.44) | (0.93) | (0.96) | +26.3% | ||||||
| Book value | — | — | (0.32) | (0.74) | (5.28) | 5.22 | 2.86 | 1.84 | 1.67 | 0.75 | 0.43 | n/m | ||||||
| Shares, m | — | — | 58 | 58 | 30 | 52 | 55 | 55 | 55 | 56 | 58 | (0.5%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 79.23 | 15.30 | 39.6 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.83 | 3.74 | 1.71 | 2.3 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 57.04 | 4.87 | 28.5 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.71 | (2.19) | (0.24) | (0.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (10) | (13) | (26) | (85) | (102) | (48) | (24) | (51) | (61) | +25.5% | |||||
| Capex | — | — | 0 | 0 | (2) | (4) | (4) | 3 | (1) | 0 | 0 | +13.3% | ||||||
| Free cash flow | — | — | (10) | (13) | (28) | (89) | (106) | (45) | (24) | (52) | (61) | +25.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 64 | 48 | 156 | 257 | 140 | 97 | 88 | 37 | 22 | (7.4%) | |||||
| Net debt | — | — | 21 | 44 | (157) | (268) | (152) | (118) | (94) | (44) | (31) | n/m | ||||||
| Shareholders’ equity | — | — | (19) | (43) | (157) | 272 | 157 | 101 | 92 | 42 | 27 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (35.21) | (40.82) | (108.69) | (89.64) | (50.78) | (41.21) | (13.67) | (70.51) | (109.34) | (35.3) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (1,355.35) | (1,401.74) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 37.93 | 79.58 | 119.48 | (355.92) | (54.96) | (47.96) | (16.14) | (82.72) | (140.51) | (120.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 62 | 108 | 100 | 81 | 62 | 64 | — | +0.6% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.42 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Connect Biopharma Holdings Limited Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HOWL Werewolf Therapeutics, Inc. | $49.6M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | Compare |
| APLM Apollomics Inc. | $49.5M | — (loss-making) | — | — | 0.00% | +76.08% (above 0%: growing) | — | — | Compare |
| TIL Instil Bio, Inc. | $47.4M | — (loss-making) | — | — | n/m | +68.62% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMA ImageneBio, Inc. | $47.3M | — (loss-making) | — (loss-making) | −60.08% (below 0%: shrinking) | n/m | +23.76% (above 0%: growing) | 100.00% | 0.00% | Compare |
| HYFT MindWalk Holdings Corp. | $47.1M | — (loss-making) | — (loss-making) | +19.37% (above 0%: growing) | n/m | +9.79% (above 0%: growing) | 58.58% | (159.86%) | Compare |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $46.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $44.8M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IBIO iBio, Inc. | $44.4M | — (loss-making) | — (loss-making) | +100.00% (above 0%: growing) | n/m | −35.33% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CRBU Caribou Biosciences, Inc. | $44.2M | — (loss-making) | — (loss-making) | −26.89% (below 0%: shrinking) | n/m | +84.78% (above 0%: growing) | 100.00% | (1,720.10%) | Compare |
| Median of peers | $47.2M | — | — | +19.37% | — | +46.19% | 100.00% | 0.00% |